SARDs are a heterogeneous group of disorders characterized by dysregulation of the immune system, that starts to turn against the body’s own tissues. Major SARDs include systemic lupus erythematosus, rheumatoid arthritis, systemic sclerosis and Sjögren’s syndrome. These diseases can affect multiple organs and share common symptoms such as fatigue, fever, joint pain and skin rash. Diagnosis relies on a combination of clinical assessment and specific autoantibody tests. Early diagnosis is crucial to initiate appropriate therapy and slow down disease progression.
The ANA Screening test is a solid-phase ELISA (SPA) designed for the initial antibody profile screening in ANA-positive patients, providing a first level of characterisation before more specific testing (ENA, dsDNA, blot, etc.). It serves as a confirmation test following indirect immunofluorescence on HEp-2 cells (IIF), improving diagnostic selectivity and reducing false positives.
Each well contains a mix of key antigens associated with SARD. The antigen mix is designed to cover the main autoantibody specificities linked to SLE, systemic sclerosis, Sjögren’s syndrome, myositis and overlap syndromes. In particular:
- RNP/Sm and Sm for SLE and MCTD
• SS-A, SS-B, Ro52 for Sjögren’s syndrome, SLE, myositis
• Scl-70 and PM-Scl for systemic sclerosis (diffuse and overlap forms)
• Jo-1 for anti-synthetase syndrome
• PCNA, CENP-B for juvenile SLE and limited SSc
• Ribosomal P protein for SLE with neuropsychiatric involvement
Serum, EDTA plasma, heparin plasma, citrate plasma
ELISA
Fasting for at least 8-12 hours before sampling
Refer to the Health Service Charter to check storage conditions
+2/+8°C
This test provides the quantitative determination of total tau protein to support the diagnosis of Alzheimer’s disease.
This test provides the quantitative determination of tau protein phosphorylated at threonine 181 (pTau181), to support the diagnosis of Alzheimer’s disease.
Test for the determination of human autoantibodies against NMDAR to support the diagnosis of paraneoplastic neurological syndromes with an intermediate-risk phenotype.
Subscribe to our newsletter to be always updated.